

**elf atochem**



**Elf Atochem North America, Inc.**

2000 Market Street  
Philadelphia, PA 19103-3222  
Tel.: 215.419.7000

**ORIGINAL**

September 15, 1994

**FEDERAL EXPRESS  
RETURN RECEIPT REQUESTED**

Document Processing Center (TS-790)  
Office of Pollution Prevention and Toxics  
Environmental Protection Agency  
401 M St. S.W.  
Washington, D.C. 20460  
Attn: Section 8(e) Coordinator

Subject: TSCA Section 8(e) Submission



8EHQ-94-12988  
INIT

**Contains No CBI**

RECEIVED  
SEP 23 11:59

Dear Sir/Madam:

Elf Atochem North America Inc. has recently received a final report from an acute inhalation toxicity study in rats and is submitting it to the Environmental Protection Agency (EPA) pursuant to Toxic Substances Control Act (TSCA) Section 8(e). Although this study was conducted in 1989 by Atochem in France, it has only just come into our possession. The study provides information on Thioglycolic acid (Mercaptoacetic acid, CAS No. 68-11-1) and does not involve effects in humans. The title of the enclosed study is Thioglycolic Acid Acute Inhalation Toxicity Study in Rats 4-Hour Exposure.

Nothing in this letter or the enclosed study report is considered confidential business information of Elf Atochem.

In this study, groups of 5 male and female rats were exposed by whole body exposure for 4-hours to aerosols of thioglycolic acid. The 4-hour  $LC_{50}$  was estimated to be 0.21 mg/l (210 mg/m<sup>3</sup>). The ACGIH Threshold Limit Value (TLV-TWA) for thioglycolic acid is 1 ppm (3.8 mg/m<sup>3</sup>), with a skin notation. The Elf Atochem MSDS for thioglycolic acid states to avoid skin and eye contact, and to avoid breathing fumes or vapors. The MSDS recommends personal protective equipment for eye, skin and the respiratory tract. The MSDS is currently being updated to include the information from the inhalation study.



88940000230

11/18/94

**elf atochem**



**Elf Atochem North America, Inc.**

2000 Market Street  
Philadelphia, PA 19103-3222  
Tel.: 215.419.7000

**ORIGINAL**

September 15, 1994

**FEDERAL EXPRESS  
RETURN RECEIPT REQUESTED**

Document Processing Center (TS-790)  
Office of Pollution Prevention and Toxics  
Environmental Protection Agency  
401 M St. S.W.  
Washington, D.C. 20460  
Attn: Section 8(e) Coordinator

Subject: TSCA Section 8(e) Submission



8EHQ-94-12988  
INIT

**Contains No CBI**

RECEIVED  
SEP 23 11:53  
EPA/PP/TSCA

Dear Sir/Madam:

Elf Atochem North America Inc. has recently received a final report from an acute inhalation toxicity study in rats and is submitting it to the Environmental Protection Agency (EPA) pursuant to Toxic Substances Control Act (TSCA) Section 8(e). Although this study was conducted in 1989 by Atochem in France, it has only just come into our possession. The study provides information on Thioglycolic acid (Mercaptoacetic acid, CAS No. 68-11-1) and does not involve effects in humans. The title of the enclosed study is Thioglycolic Acid Acute Inhalation Toxicity Study in Rats 4-Hour Exposure.

Nothing in this letter or the enclosed study report is considered confidential business information of Elf Atochem.

In this study, groups of 5 male and female rats were exposed by whole body exposure for 4-hours to aerosols of thioglycolic acid. The 4-hour  $LC_{50}$  was estimated to be 0.21 mg/l (210 mg/m<sup>3</sup>). The ACGIH Threshold Limit Value (TLV-TWA) for thioglycolic acid is 1 ppm (3.8 mg/m<sup>3</sup>), with a skin notation. The Elf Atochem MSDS for thioglycolic acid states to avoid skin and eye contact, and to avoid breathing fumes or vapors. The MSDS recommends personal protective equipment for eye, skin and the respiratory tract. The MSDS is currently being updated to include the information from the inhalation study.



88940000230

2

Elf Atochem has not previously filed any 8(e) notices or Premanufacture Notifications (PMNs) on the subject material. Further questions regarding this submission may be directed to me at (215) 419-5892.

Sincerely,



C.H. Farr, PhD, DABT  
Manager, Product Safety  
and Toxicology

Enclosure

THIOGLYCOLIC ACID  
ACUTE INHALATION TOXICITY  
IN RATS  
4-HOUR EXPOSURE

**Contains No CBI**

**Sponsor:**

S.N.E.A. (P),  
Usine de Laq,  
64170 Artix.

**Addressee:**

Dr. Regnier,  
Responsable des Etudes Toxicologie,  
Atochem,  
D.R.D.I./Service Toxicologie,  
4 et 8 Cours Michelet,  
Cedex 42,  
92091 Paris la Defense,  
FRANCE.

Report issued 13 January 1989.

**Authors:**

Graham C. Jackson,  
Colin J. Hardy,  
Rupanagudi S. Rao,  
David J. Lewis,  
Chirukandath Gopinath.

Huntingdon Research Centre Ltd.,  
Huntingdon,  
Cambridgeshire,  
PE18 6ES,  
ENGLAND.

|   | Page   |
|---|--------|
| SUMMARY   | i - ii |
| INTRODUCTION  | 1      |
| MATERIALS AND METHODS   |        |
| Test substance  | 2      |
| Animals and maintenance   | 2      |
| Inhalation exposures  | 3      |
| Exposure system   | 3      |
| Procedure   | 4      |
| Chamber atmosphere analyses                                       | 4 - 5  |
| Chamber air temperature   | 5      |
| Observations  | 5      |
| Terminal studies  | 6      |
| Estimation of the LC <sub>50</sub> (4-hour) and standard error    | 6      |
| RESULTS   |        |
| Chamber atmosphere conditions                                     |        |
| Concentration of THIOGLYCOLIC ACID                                | 7      |
| Particle size distribution  | 7      |
| Chamber air temperature   | 7      |
| Clinical observations   |        |
| Mortality   | 8      |
| Clinical signs  | 8      |
| Bodyweight  | 9      |
| Food consumption  | 9      |
| Water consumption   | 9      |
| Terminal studies  |        |
| Lung weight to bodyweight ratio                                   | 9      |
| Estimation of the LC <sub>50</sub> (4-hour) for THIOGLYCOLIC ACID | 9      |
| Macroscopic pathology   | 10     |
| Microscopic pathology   | 10     |
| FIGURES   |        |
| 1. Aerosol generator  | 11     |
| 2. Exposure system  | 12     |

## TABLES

## Page

|    |   |    |      |
|----|---|----|------|
| 1. | Concentrations of THIOGLYCOLIC ACID             | 13 |      |
| 2. | Particle size distribution of THIOGLYCOLIC ACID | 14 |      |
| 3. | Clinical signs during exposure                  | 15 | - 16 |
| 4. | Clinical signs during observation period        | 17 | - 19 |
| 5. | Individual and group mean bodyweights (g)       | 20 | - 24 |
| 6. | Group mean daily food consumption (g/rat)       | 25 |      |
| 7. | Group mean daily water consumption (g/rat)      | 25 |      |
| 8. | Lung weight to bodyweight ratios                | 26 | - 28 |

## APPENDICES

|    |   |    |      |
|----|---|----|------|
| 1. | Method of analysis for THIOGLYCOLIC ACID      | 29 | - 30 |
| 2. | Pathological data relating to individual rats | 31 | - 51 |

(6)

Test substance: A clear, colourless liquid identified as THIOGLYCOLIC ACID.

Test animals: Albino rats, (WISTAR). One control group and 4 test groups each of 5 male and 5 female rats.

Route of administration: By inhalation of a test atmosphere containing a liquid droplet aerosol generated from the test substance.

Duration of exposure: 4 hours continuous whole-body exposure.

Observation period: 14 days post exposure.

## Results

| Exposure levels and mortality: | Level<br>(mg/l) | Mortality |         |       |
|--------------------------------|-----------------|-----------|---------|-------|
|                                |                 | Males     | Females | Total |
|                                | 0.068           | 0/5       | 0/5     | 0/10  |
|                                | 0.172           | 2/5       | 2/5     | 4/10  |
|                                | 0.338           | 3/5       | 4/5     | 7/10  |
|                                | 0.582           | 5/5       | 5/5     | 10/10 |

## Clinical signs:

- (a) During exposure: signs consistent with exposure to an irritant aerosol including, partial closing of the eyes, wetness around the eyes and around the mouth, abnormal respiration, restless behaviour and the adoption of a hunched posture.
- (b) During observation period: signs seen in rats exposed to THIOGLYCOLIC ACID included abnormal respiration, brown staining around the snout and jaws and sensitivity to touch.

Recovery from the effects of the exposure, as determined by the appearance and behaviour of the rats, was complete by 3 to 13 days post exposure, depending on the exposure level.

**Bodyweight:**

Reduced bodyweight or rate of bodyweight gain, related to the exposure level, for up to 3 days following exposure. Subsequently weight gain was similar to that for control rats.

**Food and water consumption:**

Food consumption was reduced for 1 day in male rats and for up to 4 days in female rats following exposure to THIOGLYCOLIC ACID at 0.172 or 0.338 mg/l.

Water consumption was reduced for up to 2 days in male rats exposed at 0.172 or 0.338 mg/l and for 3 days in female rats following exposure at 0.338 mg/l.

**Lung weight to bodyweight ratio:**

The lung weight to bodyweight ratios for most rats that died as a result of exposure were high. The lung weights for rats that survived exposure to THIOGLYCOLIC ACID were generally within normal limits but higher than expected in a proportion of rats exposed at 0.068 mg/l.

**Estimation of the LC<sub>50</sub> (4-hour):**

The LC<sub>50</sub> (4-hour) for THIOGLYCOLIC ACID is estimated at 0.21 mg/l of air. The standard error of the estimate is 0.040 mg/l.

**Macroscopic pathology:**

The lungs of the majority of rats that died as a result of exposure were congested.

There were no macroscopic abnormalities in rats that survived exposure to THIOGLYCOLIC ACID and no abnormalities in the control rats.

**Microscopic pathology:**

The lungs of rats that died as a result of exposure were congested.

There were no other treatment-related findings.



The acute inhalation toxicity of THIOGLYCOLIC ACID was assessed by exposing 4 groups of rats each for a period of 4 hours to aerosols produced from the test substance.

The study was conducted at the Huntingdon Research Centre during the period 18 May 1988 to 16 June 1988.

The protocol for the study was approved by the Study Director and HRC Management on 15 February 1988 and approved by the Sponsor on 7 March 1988.

On completion of the study all data relating to the study, including preserved tissues and a copy of the final report, were lodged in the Huntingdon Research Centre Archives, Huntingdon, Cambridgeshire, England.

### Test substance

The test substance was a clear, colourless liquid identified as:

ACIDE THIOGLYCOLIQUE (THIOGLYCOLIC ACID)  
Reference 6218

The sample was received on 17 February 1988 and was stored in the dark at 4°C and in the original container.

The data supplied by the Sponsor indicated that the test substance was adequately stable for use in this study.

The test substance is referred to as THIOGLYCOLIC ACID in this report.

### Animals and maintenance

Twenty-five male and 25 female albino rats (Wistar), about 6 weeks and 8 weeks old respectively, were obtained from Charles River UK Limited, Manston Road, Margate, Kent, England. The rats were obtained in 2 batches. The first batch (20 male and 20 female) was received on 18 May 1988 and the second batch (5 male and 5 female) was received on 25 May 1988. The ages of rats were selected so that males and females would be of similar bodyweight (ca. 200g) on the day of exposure.

On arrival the rats were allocated to 1 of 5 groups, each of 5 males and 5 females and were identified individually by a number tattooed on the ears. The rats were housed 5 of like sex to a cage and acclimatised to laboratory conditions for at least 5 days before the day of exposure.

The cages were made of polypropylene (size 38 cm x 56 cm x 18 cm height) and had detachable wire mesh tops and floors. The cages were suspended on a movable rack. While in their cages all rats had free access to a measured excess amount of food (Labsure LAD 1) and tap water. Food and water supplies were analysed routinely to determine the levels of chemical or microbiological contaminants.

The rats remained in a holding room except for the 4-hour exposure and an overnight post exposure period when the rats exposed to THIOGLYCOLIC ACID were kept in a ventilated cabinet to allow dispersal of any residual test substance.

The mean daily maximum and minimum temperatures of the holding area during the study are shown below:

| Groups | Dates             | Mean<br>maximum<br>temperature<br>(°C) | Mean<br>minimum<br>temperature<br>(°C) | Mean<br>RH (%) |
|--------|-------------------|--|--|----------------|
| 1 - 5  | 18.5.88 - 16.6.88 | 22 (0.7)                               | 20 (0.5)                               | 55 (6.6)       |

The numbers in parentheses are the standard deviations of the mean.

### Inhalation exposures

Four groups of rats were exposed continuously for 4 hours to test atmospheres containing a liquid droplet aerosol generated from THIOGLYCOLIC ACID. Each group was exposed to a different concentration of the test substance.

A further group acting as a control received clean air only for 4 hours.

The group identifications and dates of exposure for the groups were:

|         |           |   |             |
|---------|-----------|---|-------------|
| Group 1 | (Control) | : | 24 May 1988 |
| Group 2 | (Test)    | : | 24 May 1988 |
| Group 3 | (Test)    | : | 26 May 1988 |
| Group 4 | (Test)    | : | 27 May 1988 |
| Group 5 | (Test)    | : | 2 June 1988 |

The mean concentrations of the test aerosol for each group are given in the 'Results' section of this report.

### Exposure system

#### Aerosol generator

The aerosol generator, shown in Figure 1, was designed to produce and maintain an atmosphere containing a high proportion of respirable droplets. All parts of the generator in contact with the test substance were made of stainless steel or glass.

The test substance was supplied to the generator from a syringe driven at a constant rate by a syringe pump. The compressed air supply to the generator was dried, filtered and oil-free.

#### Exposure chambers

The whole-body exposure chambers used for the exposures were of square section and were fitted with pyramidal tops. The chambers were made of perspex and had an internal volume of approximately 120 litres. Each chamber was divided by wire mesh partitions to provide 10 separate animal compartments.

The test atmosphere entered through a port at the base centre of the chamber and passed out through small holes in the lower edge of the square section. Each chamber was positioned inside a large cabinet equipped with an extract fan exhausting to atmosphere through a carbon-filled drum.

The exposure system is shown in Figure 2.

## Procedure

A supply of clean dried air was connected to the aerosol generator and the supply pressure was adjusted to give a flow rate of 30 litres per minute measured at the generator outlet tube. An in-line flow meter was used to monitor air flow throughout the exposure.

A syringe filled with the test substance was fitted to the syringe pump and connected to the generator with PTFE tubing. A flow rate of 0.2 ml/minute was selected for the exposure of the first test group.

The rats to be exposed were placed into separate compartments of the exposure chamber.

The syringe pump was switched on and the exposure timed for 4 hours, following a 11-minute<sup>(1)</sup> equilibration period, from the appearance of an aerosol from the generator outlet.

After 4 hours the supply of test substance was discontinued and the exposure chamber was allowed to clear before the rats were removed for examination.

The procedure was repeated, with appropriate flow rates of THIOGLYCOLIC ACID for each of the other test groups. The equilibration period for these groups was 9 minutes<sup>(1)</sup>.

The control group was treated similarly but exposed to air only.

Following exposure the rats were returned to the holding cages and food and water supplies were restored. The control rats were returned to the holding room. The rats exposed to THIOGLYCOLIC ACID were kept in a ventilated cabinet overnight and then returned to the holding room for the remainder of the observation period.

## Chamber atmosphere analyses

Five air samples were taken from the chamber during each exposure and the collected material was analysed to determine the concentration of THIOGLYCOLIC ACID in the chamber air.

Each air sample was withdrawn, at 2 litres per minute, through a gas absorption trap (sintered glass bubbler) containing dichloroethane as the absorbant.

The trap was cooled to -70°C (cardice/acetone) before sampling and the volume of the air sample was measured with a wet-type gas meter.

<sup>(1)</sup> 11 minutes is the theoretical time required for the concentration of aerosol in the chamber to reach 90% of its final value at an air flow rate of 25 litres per minute. At 30 litres per minute the equilibration period required is 9 minutes. The additional 2 minutes exposure received by the first test group (Group 2) was considered unlikely to have influenced the results of the study

Two additional air samples were taken during each exposure using a May multistage liquid impinger<sup>(1)</sup> with dichloroethane as the trapping agent in each stage. The samples were taken approximately 1.5 and 3.5 hours after the start of exposure.

The contents of the stages of the sampler were analysed to determine the size distribution of THIOGLYCOLIC ACID droplets in the test atmospheres.

The collection characteristics for the sampler used at a sampling rate of 10 litres per minute are:

Stage 1 - particles greater than 5.5  $\mu\text{m}$  aerodynamic diameter (a.d.)

Stage 2 - particles between 5.5  $\mu\text{m}$  and 2.0  $\mu\text{m}$  a.d.

Stage 3 - particles less than 2.0  $\mu\text{m}$  a.d.

The method of analysis for THIOGLYCOLIC ACID is described in Appendix 1.

#### Chamber air temperature

The air temperature in the exposure chamber was measured with a mercury-in-glass thermometer and recorded at the start of exposure and then at 30-minute intervals during the 4-hour exposure.

#### Observations

##### Clinical signs

The rats were observed continuously for signs of reaction to the test substance during exposure and at least twice daily throughout the observation period.

##### Bodyweight

All rats were weighed daily from the day of delivery to the Huntingdon Research Centre until the end of the observation period.

##### Food and water consumption

The amount of food and water consumed by each cage of rats was measured daily from the day following arrival. The daily mean intakes of food and water for each rat were calculated from the recorded data.

(<sup>1</sup>) May, K.R., Bacteriological Reviews 30, 3, 1966, pp 559-570.

Terminal studies

At the end of the 14-day observation period, the surviving rats were anaesthetised by intraperitoneal injection of pentobarbitone sodium and killed by exsanguination.

All rats that died as a result of exposure and those killed at the end of the observation period were subjected to a detailed macroscopic examination. The lungs were removed, dissected clear of surrounding tissue and weighed in order to calculate the lung weight to bodyweight ratio.

The lungs were infused with, and preserved in, buffered 10% formalin together with samples of the liver and kidneys for microscopic examination.

The fixed tissues were embedded in paraffin wax and processed routinely. Four-micron sections were prepared, stained with haematoxylin and eosin and examined under the light microscope.

Estimation of the LC<sub>50</sub> (4-hour) and standard error

The concentration of the test substance likely to cause death in 50% of exposed rats following a single 4-hour exposure was calculated by the log probit method of Miller and Tainter<sup>(1)</sup>.

The standard error was calculated from the formula:

$$SE \text{ of } LC_{50} = \frac{2s}{\sqrt{2N}}$$

where 2s is the estimated increment in concentration of the test substance between probits 4.0 and 6.0 corresponding to 16% and 84% mortality and N is the total number of rats in groups with mortality between 6.7% and 93.3% (Probits 3.5 - 6.5).

(<sup>1</sup>) Miller, L.C. and Tainter, M.L., Proc. Soc. Exp. Bio. Med. 57, (2), 1944, pp 261-264.

CHAMBER ATMOSPHERE CONDITIONSConcentration of THIOGLYCOLIC ACID

The analysis results for the air samples taken during the exposures are shown in Table 1.

The mean concentrations of THIOGLYCOLIC ACID in the chamber air and the variations in concentration (range x 100/mean) for each group were:

| Group | THIOGLYCOLIC<br>ACID<br>in air<br>(mg/l) | Variation<br>(%) | Relative<br>standard<br>deviation<br>(%) |
|-------|--|------------------|--|
| 2     | 0.582                                    | 53               | 21                                       |
| 3     | 0.172                                    | 116              | 48                                       |
| 4     | 0.068                                    | 134              | 53                                       |
| 5     | 0.338                                    | 56               | 22                                       |

The variations in concentration were much higher than expected and were considered to be related to the properties of the test substance. The aerosolisation process was inefficient, with average efficiencies (analysed concentration x 100/nominal concentration) of 4 - 6%, due to the viscosity of the test substance and the observed variation may be associated with temperature dependent changes in viscosity during the exposure.

However, we consider that the mean analysed concentrations provide a good estimate of the exposure levels and that the variation would not have affected the mortality following exposure to THIOGLYCOLIC ACID.

Particle size distribution

The results for the air samples taken for determination of the particle size distribution of THIOGLYCOLIC ACID are shown in Table 2.

The results show that 76 - 89% of the THIOGLYCOLIC ACID present in the chamber atmosphere was in the form of particles of respirable size (<5.5 µm aerodynamic diameter).

Chamber air temperature

The mean chamber air temperatures and the standard deviation of the means, during exposure of the groups were:

| Group          | Temperature (°C) |      |
|----------------|------------------|------|
|                | Mean             | SD   |
| 1 (Control)    | 24.0             | 0.00 |
| 2 (0.582 mg/l) | 24.8             | 0.44 |
| 3 (0.172 mg/l) | 23.3             | 1.00 |
| 4 (0.068 mg/l) | 22.7             | 0.50 |
| 5 (0.338 mg/l) | 22.0             | 0.00 |

SD Standard deviation

There were no differences in temperature considered likely to influence the results of the study.

CLINICAL OBSERVATIONSMortality

The mortality is summarised below:

| Group          | Deaths |        | Total |
|----------------|--------|--------|-------|
|                | Male   | Female |       |
| 1 (Control)    | 0/5    | 0/5    | 0/10  |
| 2 (0.582 mg/l) | 5/5    | 5/5    | 10/10 |
| 3 (0.172 mg/l) | 2/5    | 2/5    | 4/10  |
| 4 (0.068 mg/l) | 0/5    | 0/5    | 0/10  |
| 5 (0.338 mg/l) | 3/5    | 4/5    | 7/10  |

In Group 2 (0.582 mg/l) 5 male rats and 3 female rats died overnight following exposure. Two female rats were killed for humane reasons on Day 1 of the observation period.

In Group 3 (0.172 mg/l) 2 male rats and 2 female rats died overnight following exposure.

In Group 5 (0.338 mg/l) 3 male rats and 4 female rats died overnight following exposure.

Clinical signs(a) During the exposure

The incidence of clinical signs observed during exposure is shown in Table 3. The signs seen during exposure were considered to be consistent with inhalation of an irritant aerosol and included partial closing of the eyes, an irregular respiration rate, adoption of a hunched body posture, wetness (probable lacrimation) around the eyes, wet fur, due to salivation, around the snout and jaws and restless behaviour.

(b) During the observation period

The incidence of clinical signs seen during the observation period is shown in Table 4. Column 0 of this table shows the observations made when the rats were removed from the exposure chamber. At this time signs evident in rats exposed to THIOGLYCOLIC ACID at 0.172 mg/l, or higher levels included wet fur around the snout, jaws and eyes, brown staining around the snout and jaws, abnormal breathing and hyperactivity. Later some of these rats were observed to be lethargic. In rats exposed at 0.068 mg/l only brown staining and wet fur were observed.

The rats that survived exposure showed brown staining around the snout and jaws for between 2 days in rats exposed at 0.068 mg/l and up to 10 days in rats exposed at 0.338 mg/l. Other signs observed were lethargy, sensitivity to touch, wet fur, the adoption of a hunched posture, diarrhoea, ataxia and abnormal breathing. Recovery from the effects of exposure, as judged by the appearance and behaviour of the rats, was complete within 3 days in rats exposed at 0.068 mg/l and within 13 days in rats exposed at 0.338 mg/l.



### Bodyweight

The group mean and individual bodyweights are shown in Table 5.

There were decreases of bodyweight or reductions in the rate of bodyweight gain, related to the exposure level, for up to 3 days following exposure. Subsequently weight gain for rats that survived exposure to THIOGLYCOLIC ACID was similar to that of the control rats.

### Food consumption

The food consumption data are presented in Table 6.

Food consumption was reduced for 1 day in male rats and for up to 4 days in female rats following exposure to THIOGLYCOLIC ACID at 0.172 or 0.338 mg/l. Slight reductions in food consumption were observed following exposure at 0.068 mg/l.

### Water consumption

The water consumption data are presented in Table 7. Water consumption was reduced for up to 2 days in male rats exposed at 0.172 or 0.338 mg/l and for 3 days in female rats following exposure to THIOGLYCOLIC ACID at 0.338 mg/l.

## TERMINAL STUDIES

### Lung weight to bodyweight ratio

The lung weight to bodyweight ratio for individual rats is shown in Table 8.

The lung weight to bodyweight ratio was increased, due to a high lung weight, in most rats that died as a result of exposure to THIOGLYCOLIC ACID. The lung weights were generally within normal limits for the control rats and for the rats that survived exposure to THIOGLYCOLIC ACID but higher than expected in a proportion of rats exposed at 0.068 mg/l.

### Estimation of the LC<sub>50</sub> (4-hour) for THIOGLYCOLIC ACID

From the mortality data for Groups 2, 3, 4 and 5 the LC<sub>50</sub> (4-hour) for THIOGLYCOLIC ACID was established at:

0.21 mg per litre of air (210 mg/m<sup>3</sup>)

The standard error of the estimate was 0.040 mg/l.

Macroscopic pathology

The macroscopic pathological findings for individual rats are included in Appendix 2.

The findings for rats that died as a result of exposure to THIOGLYCOLIC ACID were typified by congestion of the lungs.

There were no treatment-related macroscopic abnormalities in rats that survived exposure to THIOGLYCOLIC ACID and no abnormalities in the control rats.

Microscopic pathology

The histopathological findings observed in the tissues examined are given in detail in Appendix 2.

The following comments are made in summary:

Decedent rats

Congestion in the lungs of decedent rats from groups receiving 0.582, 0.338 and 0.172 mg/L.

Animals examined at termination

No treatment-related changes were detected.

Incidental findings

All other findings observed were considered spontaneous in origin and therefore no toxicological significance.

FIGURE 1  
Aerosol generator

ATO/39

- a. Glass elutriating column.
- b. Compressed air supply.
- c. Feed tube with adjustment screw.
- d. Venturi atomising jet.
- e. Drain tubes.




FIGURE 2  
Exposure system

ATO/39




TABLE 1

ATO/39

## Concentrations of THIOGLYCOLIC ACID

| Group | Sample | Time     | Amount<br>in air<br>(mg/l) | Variation<br>(note a) |
|-------|--------|----------|----------------------------|-----------------------|
| 2     | 2.1    | 0h : 30m | 0.700                      | 53%                   |
|       | 2.2    | 1h : 00m | 0.394                      |                       |
|       | 2.3    | 2h : 00m | 0.675                      |                       |
|       | 2.4    | 3h : 00m | 0.527                      |                       |
|       | 2.5    | 3h : 50m | 0.613                      |                       |
|       | Mean   |          | 0.582                      |                       |
| 3     | 3.1    | 0h : 30m | 0.110                      | 116%                  |
|       | 3.2    | 1h : 00m | 0.109                      |                       |
|       | 3.3    | 2h : 00m | 0.171                      |                       |
|       | 3.4    | 3h : 00m | 0.160                      |                       |
|       | 3.5    | 3h : 50m | 0.309                      |                       |
|       | Mean   |          | 0.172                      |                       |
| 4     | 4.1    | 0h : 30m | 0.023                      | 134%                  |
|       | 4.2    | 1h : 00m | 0.047                      |                       |
|       | 4.3    | 2h : 00m | 0.063                      |                       |
|       | 4.4    | 3h : 00m | 0.095                      |                       |
|       | 4.5    | 3h : 50m | 0.114                      |                       |
|       | Mean   |          | 0.068                      |                       |
| 5     | 5.1    | 0h : 40m | 0.239                      | 56%                   |
|       | 5.2    | 1h : 30m | 0.291                      |                       |
|       | 5.3    | 2h : 30m | 0.356                      |                       |
|       | 5.4    | 3h : 00m | 0.377                      |                       |
|       | 5.5    | 3h : 45m | 0.428                      |                       |
|       | Mean   |          | 0.338                      |                       |

(a) Variation = range of values x 100/mean

TABLE 2

ATO/39

## Particle size distribution of THIOGLYCOLIC ACID

| Group | Sample | Time taken | Stage  | Particle size range (μm) | Amount collected (mg) | % of total | % respirable | Mean % respirable |
|-------|--------|------------|--------|--------------------------|-----------------------|------------|--------------|-------------------|
| 2     | PSD 1  | 1h : 30m   | 1      | >5.5                     | 0.794                 | 13.6       | 86.4         |                   |
|       |        |            | 2      | 2.0-5.5                  | 1.363                 | 23.3       |              |                   |
|       |        |            | 3      | <2.0                     | 3.688                 | 63.1       |              |                   |
|       |        |            | Totals | 5.845                    | 100.0                 |            |              |                   |
|       | PSD 2  | 3h : 30m   | 1      | >5.5                     | 0.431                 | 9.0        | 91.0         |                   |
|       |        |            | 2      | 2.0-5.5                  | 0.475                 | 9.9        |              |                   |
|       |        |            | 3      | <2.0                     | 3.888                 | 81.1       |              |                   |
|       |        |            | Totals | 4.794                    | 100.0                 |            |              |                   |
| 3     | PSD 1  | 1h : 30m   | 1      | >5.5                     | 0.950                 | 18.4       | 81.6         |                   |
|       |        |            | 2      | 2.0-5.5                  | 0.813                 | 15.7       |              |                   |
|       |        |            | 3      | <2.0                     | 3.400                 | 65.9       |              |                   |
|       |        |            | Totals | 5.163                    | 100.0                 |            |              |                   |
|       | PSD 2  | 3h : 30m   | 1      | >5.5                     | 0.456                 | 23.5       | 76.5         |                   |
|       |        |            | 2      | 2.0-5.5                  | 0.369                 | 19.0       |              |                   |
|       |        |            | 3      | <2.0                     | 1.113                 | 57.4       |              |                   |
|       |        |            | Totals | 1.938                    | 99.9                  |            |              |                   |
| 4     | PSD 1  | 1h : 30m   | 1      | >5.5                     | 0.131                 | 14.7       | 85.3         |                   |
|       |        |            | 2      | 2.0-5.5                  | 0.188                 | 21.0       |              |                   |
|       |        |            | 3      | <2.0                     | 0.575                 | 64.3       |              |                   |
|       |        |            | Totals | 0.894                    | 100.0                 |            |              |                   |
|       | PSD 2  | 3h : 30m   | 1      | >5.5                     | 0.706                 | 34.2       | 65.8         |                   |
|       |        |            | 2      | 2.0-5.5                  | 0.606                 | 29.4       |              |                   |
|       |        |            | 3      | <2.0                     | 0.750                 | 36.4       |              |                   |
|       |        |            | Totals | 2.062                    | 100.0                 |            |              |                   |
| 5     | PSD 1  | 2h : 00m   | 1      | >5.5                     | 1.725                 | 24.9       | 75.1         |                   |
|       |        |            | 2      | 2.0-5.5                  | 2.138                 | 30.9       |              |                   |
|       |        |            | 3      | <2.0                     | 3.063                 | 44.2       |              |                   |
|       |        |            | Totals | 6.926                    | 100.0                 |            |              |                   |
|       | PSD 2  | 3h : 30m   | 1      | >5.5                     | 2.488                 | 21.3       | 78.7         |                   |
|       |        |            | 2      | 2.0-5.5                  | 2.156                 | 18.5       |              |                   |
|       |        |            | 3      | <2.0                     | 7.013                 | 60.2       |              |                   |
|       |        |            | Totals | 11.657                   | 100.0                 |            |              |                   |

TABLE 3

ATO/39

## Clinical signs during exposure

| Group              | Signs                           | Number showing signs |      |     |     |     |     |     |
|--------------------|---------------------------------|----------------------|------|-----|-----|-----|-----|-----|
|                    |                                 | Time in hours        |      |     |     |     |     |     |
|                    |                                 | 0*                   | 0.25 | 0.5 | 1.0 | 2.0 | 3.0 | 4.0 |
| 1♂<br>(Control)    | Normal appearance and behaviour | 5                    | 5    | 5   | 5   | 5   | 5   | 5   |
| 1♀<br>(Control)    | Normal appearance and behaviour | 5                    | 5    | 5   | 5   | 5   | 5   | 5   |
| 2♂<br>(0.582 mg/l) | Wet fur                         |                      |      |     |     |     | 5   | 5   |
|                    | Wet around the eyes             |                      |      |     | 5   | 5   | 5   | 5   |
|                    | Eyes partially closed           |                      | 5    | 5   | 5   | 5   | 5   | 5   |
|                    | Wet around snout                |                      |      | 5   | 5   | 5   | 5   | 5   |
|                    | Wet around mouth                |                      |      |     | 5   | 5   | 5   | 5   |
|                    | Irregular respiration           |                      |      |     | 5   | 5   | 5   | 5   |
|                    | Hunched posture                 |                      | 5    | 5   | 5   | 5   | 5   | 5   |
|                    | Restless behaviour              | 5                    |      |     |     |     |     |     |
| 2♀<br>(0.582 mg/l) | Wet fur                         |                      |      |     |     |     | 5   | 5   |
|                    | Wet around the eyes             |                      |      |     | 5   | 5   | 5   | 5   |
|                    | Eyes partially closed           |                      | 5    | 5   | 5   | 5   | 5   | 5   |
|                    | Wet around snout                |                      |      | 5   | 5   | 5   | 5   | 5   |
|                    | Wet around mouth                |                      |      |     | 5   | 5   | 5   | 5   |
|                    | Irregular respiration           |                      |      |     | 5   | 5   | 5   | 5   |
|                    | Hunched posture                 |                      | 5    | 5   | 5   | 5   | 5   | 5   |
|                    | Restless behaviour              | 5                    |      |     |     |     |     |     |
| 3♂<br>(0.172 mg/l) | Eyes partially closed           |                      | 5    | 5   | 5   | 5   | 5   | 5   |
|                    | Wet around mouth                |                      |      | 1   | 2   | 5   | 5   | 5   |
|                    | Irregular respiration           |                      | 5    | 5   | 5   | 5   | 5   | 5   |
|                    | Hunched posture                 |                      | 5    | 5   | 5   |     |     |     |
|                    | Restless behaviour              | 5                    |      |     |     | 5   | 5   | 5   |
|                    | Pawing of cage mesh             |                      |      |     |     |     | 4   | 5   |
| 3♀<br>(0.172 mg/l) | Eyes partially closed           |                      | 5    | 5   | 5   | 5   | 5   | 5   |
|                    | Wet around mouth                |                      |      |     | 2   | 5   | 5   | 5   |
|                    | Irregular respiration           |                      | 5    | 5   | 5   | 5   | 5   | 5   |
|                    | Hunched posture                 |                      | 5    | 5   | 2   | 1   |     | 1   |
|                    | Restless behaviour              | 5                    |      |     | 3   | 4   | 5   | 4   |
|                    | Pawing of cage mesh             |                      |      |     |     |     | 1   | 2   |

\* Signs recorded during the equilibration period

TABLE 3

ATO/39

(Clinical signs during exposure - continued)

| Group                          | Signs                           | Number showing signs |      |     |     |     |     |     |
|--------------------------------|---------------------------------|----------------------|------|-----|-----|-----|-----|-----|
|                                |                                 | Time in hours        |      |     |     |     |     |     |
|                                |                                 | 0*                   | 0.25 | 0.5 | 1.0 | 2.0 | 3.0 | 4.0 |
| 4 <sup>♂</sup><br>(0.068 mg/l) | Restless behaviour              | 5                    | 1    |     |     |     |     |     |
|                                | Eyes partially closed           |                      | 5    | 5   | 5   | 5   | 5   | 5   |
|                                | Hunched posture                 |                      | 4    | 5   | 5   | 5   | 5   | 5   |
| 4 <sup>♀</sup><br>(0.068 mg/l) | Restless behaviour              | 5                    | 2    | 2   | 2   |     |     |     |
|                                | Eyes partially closed           |                      | 5    | 5   | 5   | 5   | 5   | 5   |
|                                | Hunched posture                 |                      | 3    | 3   | 3   | 5   | 5   | 5   |
| 5 <sup>♂</sup><br>(0.338 mg/l) | Normal appearance and behaviour | 5                    | 2    |     |     |     |     |     |
|                                | Eyes partially closed           |                      |      |     | 5   | 5   | 5   | 5   |
|                                | Wet fur around snout            |                      |      | 5   | 5   | 5   | 5   | 5   |
|                                | Irregular respiration           |                      | 2    | 5   | 5   | 5   | 5   | 5   |
|                                | Hunched posture                 |                      | 1    | 5   | 5   | 5   | 5   | 5   |
| 5 <sup>♀</sup><br>(0.338 mg/l) | Restless behaviour              |                      | 2    |     |     |     |     |     |
|                                | Normal appearance and behaviour | 5                    | 1    |     |     |     |     |     |
|                                | Eyes partially closed           |                      |      |     | 5   | 5   | 5   | 5   |
|                                | Wet fur around snout            |                      |      | 5   | 5   | 5   | 5   | 5   |
|                                | Irregular respiration           |                      | 4    | 5   | 5   | 5   | 5   | 5   |
|                                | Hunched posture                 |                      | 1    | 5   | 5   | 5   | 5   | 5   |
|                                | Restless behaviour              |                      | 3    |     |     |     |     |     |

\* Signs recorded during the equilibration period



TABLE 4  
Clinical signs during observation period

| Group                      | Signs   | Number showing signs      |                         |   |   |   |   |   |   |   |   |    |    |    |    |    |
|----------------------------|---|---------------------------|-------------------------|---|---|---|---|---|---|---|---|----|----|----|----|----|
|                            |   | Day of observation period |                         |   |   |   |   |   |   |   |   |    |    |    |    |    |
|                            |   | 0*                        | 1                       | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 1 $\sigma$<br>(Control)    | Normal appearance and behaviour   | 5                         | 5                       | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5  | 5  | 5  | 5  | 5  |
| 1 $\phi$<br>(Control)      | Normal appearance and behaviour   | 5                         | 5                       | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5  | 5  | 5  | 5  | 5  |
| 2 $\sigma$<br>(0.582 mg/l) | Wet fur on snout, jaws, head and<br>around eyes<br>Matted fur<br>Hyperactive<br>Lethargic<br>Dead (total)             | 5<br>5<br>5<br>5a         | 5                       | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5  | 5  | 5  | 5  | 5  |
| 2 $\phi$<br>(0.582 mg/l)   | Wet fur on snout, jaws, head and<br>around eyes<br>Matted fur<br>Hyperactive<br>Lethargic<br>Immobile<br>Dead (total) | 5<br>5<br>5<br>5a<br>2a   | 2<br>2<br>5<br>5a<br>5b | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5  | 5  | 5  | 5  | 5  |

\* Signs recorded after exposure on the day of exposure

a These signs were recorded at the late afternoon check

b Total includes 2 rats that died after the clinical signs had been recorded

TABLE 4

(Clinical signs during observation period - continued)

| Group              | Signs   | Number showing signs      |   |   |   |   |   |   |   |   |   |    |    |    |    |    |
|--------------------|---|---------------------------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|
|                    |   | Day of observation period |   |   |   |   |   |   |   |   |   |    |    |    |    |    |
|                    |   | 0*                        | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 3♂<br>(0.172 mg/l) | Normal appearance and behaviour                   |                           |   |   |   | 2 | 2 | 3 | 3 | 3 | 3 | 3  | 3  | 3  | 3  | 3  |
|                    | Hyperactive                                       | 5                         |   |   |   |   |   |   |   |   |   |    |    |    |    |    |
|                    | Brown staining around snout and/or jaws           | 5                         | 5 | 3 | 3 | 1 | 1 |   |   |   |   |    |    |    |    |    |
|                    | Wet fur around snout, jaws and eyes               | 5                         | 1 |   |   |   |   |   |   |   |   |    |    |    |    |    |
|                    | Lethargic   | 1                         | 1 |   |   |   |   |   |   |   |   |    |    |    |    |    |
| 3♀<br>(0.172 mg/l) | Sensitive to touch                                |                           |   |   |   |   |   |   |   |   |   |    |    |    |    |    |
|                    | Increased respiration rate                        |                           |   |   | 3 | 3 |   |   |   |   |   |    |    |    |    |    |
|                    | Dead (total)                                      | 2a                        | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2  | 2  | 2  | 2  | 2  |
|                    | Normal appearance and behaviour                   |                           |   |   |   |   |   |   |   |   |   |    |    |    |    |    |
|                    | Hyperactive                                       | 5                         |   |   |   |   |   |   |   |   |   |    |    |    |    |    |
| 4♂<br>(0.068 mg/l) | Crusty brown staining around snout, jaws and eyes | 5                         | 5 | 3 | 3 | 1 |   |   |   |   |   |    |    |    |    |    |
|                    | Wet fur around snout, jaws and eyes               | 5                         | 5 |   |   |   |   |   |   |   |   |    |    |    |    |    |
|                    | Sensitive to touch                                |                           |   |   |   |   |   |   |   |   |   |    |    |    |    |    |
|                    | Increased respiration rate                        |                           | 3 | 3 |   |   |   |   |   |   |   |    |    |    |    |    |
|                    | Dead (total)                                      | 2                         | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2  | 2  | 2  | 2  | 2  |
| 4♂<br>(0.068 mg/l) | Normal appearance and behaviour                   |                           |   | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5  | 5  | 5  | 5  | 5  |
|                    | Brown staining around snout and/or jaws           | 5                         | 5 | 5 |   |   |   |   |   |   |   |    |    |    |    |    |
|                    | Wet fur around snout, jaws and eyes               | 5                         |   |   |   |   |   |   |   |   |   |    |    |    |    |    |
| 4♀<br>(0.068 mg/l) | Normal appearance and behaviour                   |                           |   |   |   |   |   |   |   |   |   |    |    |    |    |    |
|                    | Brown staining around snout and/or jaws           | 5                         | 5 |   |   |   |   |   |   |   |   |    |    |    |    |    |
|                    | Wet fur around snout, jaws and eyes               | 5                         |   |   |   |   |   |   |   |   |   |    |    |    |    |    |

\* Signs recorded after exposure on the day of exposure  
 a These rats died after the clinical signs had been recorded

TABLE 4  
(Clinical signs during observation period - continued)

| Group              | Signs                                   | Number showing signs      |   |   |   |   |   |   |   |   |   |    |    |    |       |
|--------------------|---|---------------------------|---|---|---|---|---|---|---|---|---|----|----|----|-------|
|                    |   | Day of observation period |   |   |   |   |   |   |   |   |   |    |    |    |       |
|                    |   | 0*                        | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 14 |
| 5♂<br>(0.338 mg/l) | Normal appearance and behaviour         |                           |   |   |   |   |   |   |   |   |   |    |    |    | 2 2   |
|                    | Brown staining around snout and/or jaws | 5                         | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |   |    |    |    |       |
|                    | Wet fur                                 | 5                         | 2 |   |   |   |   |   |   |   |   |    |    |    |       |
|                    | Irregular respiration                   | 5                         | 2 | 2 | 2 |   |   |   |   |   |   |    |    |    |       |
|                    | Hyperactive                             | 5                         |   |   |   |   |   |   |   |   |   |    |    |    |       |
|                    | Lethargic                               | 5a                        | 2 | 2 | 2 |   |   |   |   |   |   |    |    |    |       |
| 5♀<br>(0.338 mg/l) | Exaggerated respiratory movements       | 3                         | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3  | 3  | 3  | 3     |
|                    | Dead (total)                            |                           |   |   |   |   |   |   |   |   |   |    |    |    |       |
|                    | Normal appearance and behaviour         |                           |   |   |   |   |   |   |   |   |   |    |    |    | 1 1   |
|                    | Brown staining around snout and/or jaws | 5                         | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1  |    |    |       |
|                    | Wet fur                                 | 5                         | 1 |   |   |   |   |   |   |   |   |    |    |    |       |
|                    | Irregular respiration                   | 5                         | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1  | 1  | 1  | 1     |
|                    | Hyperactive                             | 5                         |   |   |   |   |   |   |   |   |   |    |    |    |       |
|                    | Ataxia                                  | 1                         | 1 | 1 | 1 | 1 | 1 | 1 | 1 |   |   |    |    |    |       |
|                    | Lethargic                               | 5a                        | 1 | 1 | 1 | 1 |   |   |   |   |   |    |    |    |       |
|                    | Yellow staining around urogenital area  |                           |   |   |   |   |   |   |   |   |   |    |    |    |       |
|                    | Hunched body posture                    |                           |   |   |   |   |   |   |   |   |   |    |    |    |       |
|                    | Sensitive to touch                      |                           |   |   |   |   |   |   |   |   |   |    |    |    |       |
|                    | Diarrhoea                               |                           |   |   |   |   |   |   |   |   |   |    |    |    |       |
|                    | Red staining on tray paper              |                           |   |   |   |   |   |   |   |   |   |    |    |    |       |
|                    | Dead (total)                            | 4                         | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4  | 4  | 4  | 4     |
|                    |   |                           |   |   |   |   |   |   |   |   |   |    |    |    |       |

\* Signs recorded after exposure on the day of exposure  
a This sign was recorded at the late afternoon check

TABLE 5  
Individual and group mean bodyweights (g)

| Group           | Rat  | Day of observation period |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----------------|------|---------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|                 |      | -5                        | -4  | -3  | -2  | -1  | 0   | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  | 13  | 14  |
| 1♂<br>(Control) | 21   | 159                       | 168 | 179 | 185 | 195 | 203 | 208 | 217 | 225 | 227 | 239 | 243 | 249 | 258 | 266 | 270 | 274 | 280 | 283 | 291 |
|                 | 22   | 157                       | 161 | 170 | 181 | 189 | 199 | 204 | 210 | 218 | 228 | 236 | 245 | 253 | 264 | 272 | 279 | 289 | 296 | 301 | 311 |
|                 | 23   | 154                       | 166 | 177 | 180 | 187 | 195 | 201 | 208 | 230 | 234 | 233 | 235 | 241 | 247 | 252 | 256 | 265 | 273 | 280 | 285 |
|                 | 24   | 151                       | 163 | 178 | 180 | 191 | 198 | 205 | 212 | 220 | 225 | 231 | 244 | 257 | 267 | 276 | 282 | 284 | 293 | 302 | 307 |
|                 | 25   | 162                       | 169 | 178 | 186 | 192 | 200 | 209 | 221 | 225 | 237 | 245 | 253 | 261 | 269 | 279 | 288 | 291 | 297 | 302 | 310 |
|                 | Mean | 157                       | 165 | 176 | 182 | 191 | 199 | 205 | 214 | 224 | 230 | 237 | 244 | 252 | 261 | 269 | 275 | 281 | 288 | 294 | 301 |
| 1♀<br>(Control) | 26   | 183                       | 188 | 194 | 191 | 196 | 200 | 199 | 198 | 203 | 206 | 208 | 206 | 210 | 210 | 209 | 207 | 212 | 217 | 218 | 217 |
|                 | 27   | 174                       | 179 | 184 | 185 | 191 | 192 | 193 | 200 | 199 | 204 | 208 | 207 | 208 | 215 | 220 | 226 | 230 | 233 | 239 | 241 |
|                 | 28   | 166                       | 174 | 179 | 185 | 189 | 190 | 193 | 196 | 193 | 192 | 203 | 205 | 208 | 204 | 213 | 219 | 218 | 217 | 223 | 232 |
|                 | 29   | 174                       | 177 | 182 | 190 | 192 | 199 | 201 | 201 | 205 | 211 | 214 | 215 | 216 | 221 | 222 | 224 | 223 | 227 | 233 | 235 |
|                 | 30   | 186                       | 191 | 196 | 208 | 215 | 218 | 220 | 229 | 232 | 229 | 234 | 238 | 241 | 240 | 243 | 246 | 248 | 248 | 254 | 258 |
|                 | Mean | 177                       | 182 | 187 | 192 | 197 | 200 | 201 | 205 | 206 | 208 | 213 | 214 | 217 | 218 | 221 | 224 | 226 | 228 | 233 | 237 |

TABLE 5  
(Bodyweights - continued)

| Group                          | Rat  | Day of observation period |     |     |     |     |     |      |      |   |   |   |   |   |   |   |    |    |    |    |    |
|--------------------------------|------|---------------------------|-----|-----|-----|-----|-----|------|------|---|---|---|---|---|---|---|----|----|----|----|----|
|                                |      | -5                        | -4  | -3  | -2  | -1  | 0   | 1    | 2    | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 2 <sup>σ</sup><br>(0.582 mg/l) | 31   | 156                       | 166 | 178 | 188 | 201 | 208 | DEAD |      |   |   |   |   |   |   |   |    |    |    |    |    |
|                                | 32   | 154                       | 166 | 178 | 184 | 193 | 202 | DEAD |      |   |   |   |   |   |   |   |    |    |    |    |    |
|                                | 33   | 147                       | 156 | 169 | 173 | 180 | 188 | DEAD |      |   |   |   |   |   |   |   |    |    |    |    |    |
|                                | 34   | 156                       | 163 | 174 | 182 | 187 | 196 | DEAD |      |   |   |   |   |   |   |   |    |    |    |    |    |
|                                | 35   | 153                       | 164 | 176 | 182 | 193 | 199 | DEAD |      |   |   |   |   |   |   |   |    |    |    |    |    |
|                                | Mean | 153                       | 163 | 175 | 182 | 191 | 199 | DEAD |      |   |   |   |   |   |   |   |    |    |    |    |    |
| 2 <sup>♂</sup><br>(0.582 mg/l) | 36   | 182                       | 191 | 194 | 194 | 197 | 203 | 179  | DEAD |   |   |   |   |   |   |   |    |    |    |    |    |
|                                | 37   | 173                       | 176 | 182 | 183 | 192 | 194 | DEAD |      |   |   |   |   |   |   |   |    |    |    |    |    |
|                                | 38   | 178                       | 185 | 191 | 190 | 196 | 197 | DEAD |      |   |   |   |   |   |   |   |    |    |    |    |    |
|                                | 39   | 173                       | 179 | 187 | 190 | 197 | 201 | 179  | DEAD |   |   |   |   |   |   |   |    |    |    |    |    |
|                                | 40   | 168                       | 176 | 182 | 189 | 183 | 187 | DEAD |      |   |   |   |   |   |   |   |    |    |    |    |    |
|                                | Mean | 175                       | 181 | 187 | 189 | 193 | 196 | 179  |      |   |   |   |   |   |   |   |    |    |    |    |    |

TABLE 5  
(Bodyweights - continued)

| Group              | Rat  | Day of observation period |     |     |     |     |     |      |     |     |     |     |     |     |     |     |     |     |     |     |     |
|--------------------|------|---------------------------|-----|-----|-----|-----|-----|------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|                    |      | -5                        | -4  | -3  | -2  | -1  | 0   | 1    | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  | 13  | 14  |
| 3♂<br>(0.172 mg/l) | 41   | 155                       | 166 | 176 | 184 | 195 | 203 | 178  | 194 | 206 | 215 | 226 | 231 | 242 | 244 | 261 | 268 | 276 | 287 | 295 | 300 |
|                    | 42   | 164                       | 162 | 174 | 180 | 190 | 197 | DEAD |     |     |     |     |     |     |     |     |     |     |     |     |     |
|                    | 43   | 153                       | 165 | 173 | 182 | 191 | 193 | 195  | 204 | 208 | 216 | 222 | 230 | 241 | 247 | 258 | 270 | 275 | 289 | 293 | 301 |
|                    | 44   | 156                       | 162 | 174 | 181 | 192 | 202 | 170  | 181 | 197 | 213 | 220 | 228 | 237 | 247 | 260 | 270 | 277 | 287 | 291 | 302 |
|                    | 45   | 156                       | 165 | 176 | 185 | 194 | 203 | DEAD |     |     |     |     |     |     |     |     |     |     |     |     |     |
|                    | Mean | 157                       | 164 | 175 | 182 | 192 | 200 | 181  | 193 | 204 | 215 | 223 | 230 | 240 | 246 | 260 | 269 | 276 | 288 | 293 | 301 |
| 3♀<br>(0.172 mg/l) | 46   | 176                       | 178 | 185 | 191 | 197 | 191 | 203  | 200 | 206 | 207 | 206 | 220 | 220 | 219 | 215 | 219 | 223 | 225 | 223 | 228 |
|                    | 47   | 180                       | 179 | 182 | 180 | 188 | 189 | DEAD |     |     |     |     |     |     |     |     |     |     |     |     |     |
|                    | 48   | 180                       | 179 | 180 | 175 | 185 | 189 | 190  | 185 | 187 | 190 | 191 | 192 | 194 | 195 | 198 | 199 | 203 | 212 | 209 | 209 |
|                    | 49   | 187                       | 190 | 198 | 197 | 203 | 207 | DEAD |     |     |     |     |     |     |     |     |     |     |     |     |     |
|                    | 50   | 176                       | 177 | 181 | 184 | 187 | 191 | 193  | 198 | 202 | 204 | 209 | 207 | 210 | 207 | 216 | 219 | 217 | 222 | 225 | 230 |
|                    | Mean | 180                       | 181 | 185 | 185 | 192 | 193 | 195  | 194 | 198 | 200 | 202 | 206 | 208 | 207 | 210 | 212 | 214 | 220 | 219 | 222 |

TABLE 5  
(Bodyweights - continued)

| Group              | Rat  | Day of observation period |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|--------------------|------|---------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|                    |      | -5                        | -4  | -3  | -2  | -1  | 0   | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  | 13  | 14  |
| 4♂<br>(0.068 mg/l) | 51   | 168                       | 175 | 181 | 192 | 201 | 207 | 215 | 221 | 226 | 231 | 242 | 248 | 251 | 263 | 269 | 274 | 287 | 294 | 305 | 312 |
|                    | 52   | 164                       | 169 | 177 | 189 | 198 | 205 | 216 | 223 | 226 | 238 | 243 | 250 | 258 | 266 | 272 | 278 | 288 | 295 | 300 | 304 |
|                    | 53   | 163                       | 169 | 180 | 186 | 196 | 203 | 211 | 219 | 224 | 239 | 242 | 250 | 251 | 266 | 271 | 283 | 292 | 298 | 311 | 315 |
|                    | 54   | 165                       | 170 | 179 | 192 | 202 | 208 | 209 | 209 | 219 | 225 | 231 | 238 | 248 | 255 | 263 | 266 | 278 | 285 | 289 | 293 |
|                    | 55   | 174                       | 181 | 190 | 201 | 212 | 220 | 222 | 232 | 240 | 246 | 255 | 262 | 275 | 280 | 293 | 299 | 312 | 316 | 326 | 333 |
|                    | Mean | 167                       | 173 | 181 | 192 | 202 | 209 | 215 | 221 | 227 | 236 | 243 | 250 | 257 | 266 | 274 | 280 | 291 | 298 | 306 | 311 |
| 4♀<br>(0.068 mg/l) | 56   | 183                       | 189 | 194 | 199 | 195 | 202 | 209 | 212 | 219 | 214 | 218 | 220 | 225 | 222 | 224 | 228 | 236 | 231 | 241 | 246 |
|                    | 57   | 181                       | 187 | 194 | 195 | 197 | 201 | 208 | 208 | 210 | 218 | 217 | 220 | 219 | 220 | 225 | 227 | 228 | 230 | 235 | 234 |
|                    | 58   | 182                       | 189 | 191 | 190 | 194 | 198 | 203 | 199 | 201 | 203 | 204 | 199 | 203 | 205 | 210 | 205 | 214 | 231 | 233 | 215 |
|                    | 59   | 181                       | 187 | 189 | 192 | 192 | 195 | 198 | 204 | 204 | 209 | 207 | 209 | 211 | 212 | 212 | 217 | 226 | 229 | 230 | 231 |
|                    | 60   | 185                       | 190 | 187 | 188 | 199 | 197 | 206 | 210 | 213 | 218 | 211 | 216 | 225 | 227 | 224 | 228 | 231 | 232 | 228 | 231 |
|                    | Mean | 182                       | 188 | 191 | 193 | 195 | 199 | 205 | 207 | 209 | 212 | 211 | 213 | 217 | 217 | 219 | 221 | 227 | 231 | 233 | 231 |

TABLE 5  
(Bodyweights - continued)

| Group                      | Rat  | Day of observation period |     |     |     |     |     |      |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----------------------------|------|---------------------------|-----|-----|-----|-----|-----|------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|                            |      | -5                        | -4  | -3  | -2  | -1  | 0   | 1    | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  | 13  | 14  |
| 5 $\sigma$<br>(0.338 mg/l) | 61   | 154                       | 161 | 171 | 179 | 187 | 192 | DEAD |     |     |     |     |     |     |     |     |     |     |     |     |     |
|                            | 62   | 165                       | 174 | 183 | 187 | 195 | 203 | DEAD |     |     |     |     |     |     |     |     |     |     |     |     |     |
|                            | 63   | 164                       | 173 | 180 | 190 | 196 | 204 | DEAD |     |     |     |     |     |     |     |     |     |     |     |     |     |
|                            | 64   | 158                       | 164 | 172 | 177 | 183 | 191 | 192  | 195 | 204 | 212 | 212 | 216 | 222 | 227 | 231 | 233 | 240 | 245 | 251 | 254 |
|                            | 65   | 158                       | 162 | 168 | 174 | 179 | 184 | 181  | 181 | 189 | 198 | 198 | 205 | 208 | 215 | 220 | 224 | 229 | 231 | 233 | 235 |
|                            | Mean | 160                       | 167 | 175 | 181 | 188 | 195 | 187  | 188 | 197 | 205 | 205 | 211 | 215 | 221 | 226 | 229 | 235 | 238 | 242 | 245 |
| 5 $\phi$<br>(0.338 mg/l)   | 66   | 181                       | 186 | 187 | 191 | 190 | 192 | 174  | 168 | 166 | 170 | 185 | 191 | 194 | 196 | 200 | 204 | 208 | 209 | 215 | 218 |
|                            | 67   | 178                       | 180 | 186 | 188 | 184 | 188 | DEAD |     |     |     |     |     |     |     |     |     |     |     |     |     |
|                            | 68   | 179                       | 183 | 183 | 187 | 195 | 197 | DEAD |     |     |     |     |     |     |     |     |     |     |     |     |     |
|                            | 69   | 187                       | 195 | 202 | 201 | 192 | 201 | DEAD |     |     |     |     |     |     |     |     |     |     |     |     |     |
|                            | 70   | 189                       | 194 | 200 | 200 | 194 | 200 | DEAD |     |     |     |     |     |     |     |     |     |     |     |     |     |
|                            | Mean | 183                       | 188 | 192 | 193 | 191 | 196 | 174  | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   |



TABLE 6

ATO/39

Group mean daily food consumption (g/rat)

| Group              | Days         |    |    |    |    |               |    |    |    |    |    |    |    |    |    |    |    |    |    |
|--------------------|--------------|----|----|----|----|---------------|----|----|----|----|----|----|----|----|----|----|----|----|----|
|                    | Pre-exposure |    |    |    |    | Post exposure |    |    |    |    |    |    |    |    |    |    |    |    |    |
|                    | -5           | -4 | -3 | -2 | -1 | 1             | 2  | 3  | 4  | 5  | 6  | 7  | 8  | 9  | 10 | 11 | 12 | 13 | 14 |
| 1♂<br>(Control)    | 23           | 24 | 26 | 26 | 25 | 25            | 22 | 25 | 24 | 27 | 26 | 28 | 27 | 27 | 26 | 28 | 27 | 28 | 29 |
| 2♂<br>(0.582 mg/l) | 21           | 24 | 25 | 24 | 24 | 0             |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 3♂<br>(0.172 mg/l) | 24           | 25 | 24 | 25 | 24 | 3             | 21 | 24 | 25 | 24 | 27 | 27 | 27 | 28 | 28 | 29 | 31 | 31 | 31 |
| 4♂<br>(0.068 mg/l) | 25           | 25 | 26 | 26 | 25 | 19            | 20 | 22 | 23 | 28 | 25 | 26 | 28 | 27 | 29 | 33 | 32 | 32 | 31 |
| 5♂<br>(0.338 mg/l) | 22           | 22 | 22 | 23 | 23 | 6             | 20 | 21 | 23 | 22 | 23 | 22 | 24 | 22 | 23 | 24 | 24 | 22 | 27 |
| 1♀<br>(Control)    | 24           | 24 | 24 | 24 | 21 | 21            | 20 | 19 | 20 | 22 | 20 | 22 | 20 | 22 | 20 | 21 | 20 | 24 | 24 |
| 2♀<br>(0.582 mg/l) | 21           | 24 | 22 | 21 | 20 | 0             |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 3♀<br>(0.172 mg/l) | 21           | 23 | 18 | 21 | 17 | 10            | 25 | 18 | 18 | 19 | 18 | 20 | 18 | 19 | 21 | 20 | 23 | 21 | 21 |
| 4♀<br>(0.068 mg/l) | 23           | 19 | 19 | 19 | 21 | 16            | 18 | 17 | 19 | 20 | 18 | 19 | 19 | 19 | 20 | 23 | 21 | 22 | 20 |
| 5♀<br>(0.338 mg/l) | 22           | 22 | 20 | 16 | 21 | 1             | 3  | 8  | 16 | 26 | 24 | 24 | 23 | 27 | 25 | 25 | 26 | 26 | 28 |

TABLE 7

Group mean daily water consumption (g/rat)

| Group              | Days         |    |    |    |    |               |    |    |    |    |    |    |    |    |    |    |    |    |    |
|--------------------|--------------|----|----|----|----|---------------|----|----|----|----|----|----|----|----|----|----|----|----|----|
|                    | Pre-exposure |    |    |    |    | Post exposure |    |    |    |    |    |    |    |    |    |    |    |    |    |
|                    | -5           | -4 | -3 | -2 | -1 | 1             | 2  | 3  | 4  | 5  | 6  | 7  | 8  | 9  | 10 | 11 | 12 | 13 | 14 |
| 1♂<br>(Control)    | 26           | 27 | 29 | 31 | 50 | 31            | 32 | 37 | 35 | 36 | 39 | 36 | 41 | 40 | 37 | 40 | 39 | 43 | 41 |
| 2♂<br>(0.582 mg/l) | 24           | 26 | 28 | 29 | 29 | 0             |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 3♂<br>(0.172 mg/l) | 27           | 28 | 28 | 29 | 26 | 9             | 25 | 34 | 32 | 33 | 34 | 34 | 35 | 35 | 35 | 37 | 39 | 36 | 35 |
| 4♂<br>(0.068 mg/l) | 27           | 30 | 30 | 32 | 32 | 30            | 31 | 31 | 33 | 34 | 34 | 33 | 37 | 34 | 36 | 40 | 38 | 39 | 38 |
| 5♂<br>(0.338 mg/l) | 28           | 29 | 29 | 32 | 34 | 12            | 24 | 31 | 33 | 34 | 30 | 31 | 33 | 30 | 30 | 33 | 35 | 32 | 31 |
| 1♀<br>(Control)    | 32           | 36 | 37 | 36 | 35 | 35            | 37 | 30 | 33 | 39 | 37 | 35 | 31 | 37 | 37 | 40 | 37 | 43 | 42 |
| 2♀<br>(0.582 mg/l) | 31           | 34 | 31 | 32 | 33 | 0             |    |    |    |    |    |    |    |    |    |    |    |    |    |
| 3♀<br>(0.172 mg/l) | 27           | 29 | 24 | 24 | 26 | 26            | 27 | 27 | 23 | 24 | 23 | 28 | 26 | 28 | 28 | 29 | 32 | 29 | 32 |
| 4♀<br>(0.068 mg/l) | 30           | 30 | 28 | 28 | 31 | 30            | 29 | 25 | 28 | 27 | 31 | 31 | 30 | 31 | 33 | 36 | 35 | 37 | 32 |
| 5♀<br>(0.338 mg/l) | 26           | 24 | 25 | 18 | 28 | 5             | 3  | 13 | 26 | 20 | 28 | 25 | 24 | 41 | 26 | 27 | 27 | 27 | 30 |

TABLE 8

ATO/39

## Lung weight to bodyweight ratios

| Group ,                    | Rat | Lung weight (g) | Body-weight (g) | Lung to bodyweight ratio (LW x 100/BW) |           |
|----------------------------|-----|-----------------|-----------------|--|-----------|
|                            |     |                 |                 | Survivors                              | Decedents |
| 1 $\sigma$<br>(Control)    | 21  | 1.50            | 291             | 0.52                                   |           |
|                            | 22  | 1.63            | 311             | 0.52                                   |           |
|                            | 23  | 1.36            | 285             | 0.48                                   |           |
|                            | 24  | 1.47            | 307             | 0.48                                   |           |
|                            | 25  | 1.55            | 310             | 0.50                                   |           |
|                            |     |                 | Mean            | 0.50                                   |           |
|                            |     |                 | SD              | 0.020                                  |           |
| 1 $\sigma$<br>(Control)    | 26  | 1.10            | 217             | 0.51                                   |           |
|                            | 27  | 1.17            | 241             | 0.49                                   |           |
|                            | 28  | 1.18            | 232             | 0.51                                   |           |
|                            | 29  | 1.26            | 235             | 0.54                                   |           |
|                            | 30  | 1.24            | 258             | 0.48                                   |           |
|                            |     |                 | Mean            | 0.50                                   |           |
|                            |     |                 | SD              | 0.022                                  |           |
| 2 $\sigma$<br>(0.582 mg/l) | 31  | 2.70            | 208             |  | 1.30      |
|                            | 32  | 2.10            | 202             |  | 1.04      |
|                            | 33  | 2.00            | 188             |  | 1.06      |
|                            | 34  | 1.82            | 196             |  | 0.93      |
|                            | 35  | 1.25            | 199             |  | 0.63      |
|                            |     |                 | Mean            |  | 0.99      |
|                            |     |                 | SD              |  | 0.244     |
| 2 $\sigma$<br>(0.582 mg/l) | 36  | 1.06            | 179             |  | 0.59      |
|                            | 37  | 1.71            | 194             |  | 0.88      |
|                            | 38  | 2.16            | 197             |  | 1.10      |
|                            | 39  | 1.10            | 201             |  | 0.55      |
|                            | 40  | 1.96            | 187             |  | 1.05      |
|                            |     |                 | Mean            |  | 0.83      |
|                            |     |                 | SD              |  | 0.254     |

SD Standard deviation

TABLE 8

ATO/39

(Lung weight to bodyweight ratios - continued)

| Group                      | Rat | Lung weight (g) | Body-weight (g) | Lung to bodyweight ratio (LW x 100/BW) |           |
|----------------------------|-----|-----------------|-----------------|--|-----------|
|                            |     |                 |                 | Survivors                              | Decedents |
| 3 $\sigma$<br>(0.172 mg/l) | 41  | 1.37            | 300             | 0.46                                   |           |
|                            | 42  | 1.42            | 197             |  | 0.72      |
|                            | 43  | 1.43            | 301             | 0.43                                   |           |
|                            | 44  | 1.51            | 302             | 0.50                                   |           |
|                            | 45  | 1.13            | 203             |  | 0.56      |
|                            |     |                 | Mean            | 0.48                                   | 0.64      |
|                            |     |                 | SD              | 0.022                                  | -         |
| 3 $\sigma$<br>(0.172 mg/l) | 46  | 1.06            | 228             | 0.46                                   |           |
|                            | 47  | 1.43            | 189             |  | 0.76      |
|                            | 48  | 1.10            | 209             | 0.53                                   |           |
|                            | 49  | 1.70            | 207             |  | 0.82      |
|                            | 50  | 1.20            | 230             | 0.52                                   |           |
|                            |     |                 | Mean            | 0.50                                   | 0.79      |
|                            |     |                 | SD              | 0.038                                  | -         |
| 4 $\sigma$<br>(0.068 mg/l) | 51  | 1.52            | 305             | 0.50                                   |           |
|                            | 52  | 1.52            | 300             | 0.51                                   |           |
|                            | 53  | 1.91            | 311             | 0.61                                   |           |
|                            | 54  | 1.91            | 289             | 0.66                                   |           |
|                            | 55  | 1.85            | 326             | 0.57                                   |           |
|                            |     |                 | Mean            | 0.57                                   |           |
|                            |     |                 | SD              | 0.070                                  |           |
| 4 $\sigma$<br>(0.068 mg/l) | 56  | 1.35            | 241             | 0.56                                   |           |
|                            | 57  | 1.45            | 235             | 0.62                                   |           |
|                            | 58  | 1.37            | 214             | 0.64                                   |           |
|                            | 59  | 1.77            | 230             | 0.77                                   |           |
|                            | 60  | 2.04            | 228             | 0.89                                   |           |
|                            |     |                 | Mean            | 0.70                                   |           |
|                            |     |                 | SD              | 0.135                                  |           |

SD Standard deviation

TABLE 8

ATO/39

(Lung weight to bodyweight ratios - continued)

| Group                      | Rat | Lung weight (g) | Body-weight (g) | Lung to bodyweight ratio (LW x 100/BW) |           |
|----------------------------|-----|-----------------|-----------------|--|-----------|
|                            |     |                 |                 | Survivors                              | Decedents |
| 5 $\sigma$<br>(0.338 mg/l) | 61  | 1.90            | 192             |  | 0.99      |
|                            | 62  | 2.40            | 203             |  | 1.18      |
|                            | 63  | 2.30            | 204             |  | 1.13      |
|                            | 64  | 1.14            | 254             | 0.45                                   |           |
|                            | 65  | 1.32            | 235             | 0.56                                   |           |
|                            |     |                 | Mean            | 0.51                                   | 1.10      |
|                            |     |                 | SD              | -                                      | 0.099     |
| 5 $\pi$<br>(0.338 mg/l)    | 66  | 1.37            | 218             | 0.63                                   |           |
|                            | 67  | 1.35            | 188             |  | 0.72      |
|                            | 68  | 1.35            | 197             |  | 0.69      |
|                            | 69  | 1.42            | 201             |  | 0.71      |
|                            | 70  | 2.12            | 200             |  | 1.06      |
|                            |     |                 | Mean            | -                                      | 0.80      |
|                            |     |                 | SD              | -                                      | 0.177     |

SD Standard deviation

## APPENDICES

## Method of analysis for THIOGLYCOLIC ACID

1. Instrumentation and apparatus

Gas chromatograph: Pye Unicam fitted with a flame ionisation detector.  
Pye Unicam PU 4700.

Integrator: Spectra-Physics SP 4200.

Apparatus: Volumetric flasks and pipettes.  
Diazomethane generator.

2. Reagents

Dichloroethane: 'AR' grade Fisons.

Acetic acid (glacial): 'AR' grade Fisons.

Ethanol: James Burroughs Ltd.

Diethyl ether: May & Baker Ltd.

Potassium hydroxide: 'AR' grade Fisons.

Diazald: Aldrich Chemical Company.

Thioglycolic acid: Supplied by Sponsor.

3. Preparation of sample solutions for GLC

The contents of the gas absorption traps were allowed to return to room temperature, transferred quantitatively to 25 ml volumetric flasks and diluted to volume with dichloroethane. A 4 ml aliquot of the solution was transferred to a 5 ml volumetric flask and 5 µl of acetic acid was added. Diazomethane in nitrogen<sup>(1)</sup> was passed into the solution until a permanent pale yellow colour persisted. The flask was allowed to stand for 20 minutes at room temperature and the excess diazomethane was removed by the addition of a few µl of acetic acid. The solution was diluted to 5 ml with dichloroethane.

(<sup>1</sup>) The diazomethane entrained in nitrogen was generated using a method based on that described by Schlenk and Gellerman (Anal. Chem., 32 1412 (1960)). Diazald (0.5 g) is added to a mixture of ethanol (6 ml) and ether (6 ml) contained in the diazomethane generator. 0.5 ml of 60% aqueous potassium hydroxide is added just prior to use and the diazomethane is displaced by passing a stream of nitrogen through the reaction mixture.

## (Method of analysis - continued)

4. GLC4.1. Operating conditions

Column: 2 m x 3 mm i.d. glass packed with 5% FFAP on DCLQ 80 - 100 mesh.

Temperatures: Column 120°C  
Injector 150°C  
Detector 150°C

Gases: Helium (carrier) 30 ml/minute  
Hydrogen 33 ml/minute  
Air 300 ml/minute

Retention time for  
thioglycolic acid: 3.5 minutes.

4.2. Analysis of samples

A 3 µl aliquot of each sample solution was injected onto the GLC.

The amount of thioglycolic acid in the aliquot was evaluated using an external standard method.

The calculation was:

$$C_x = A_x/A_s$$

where  $C_x$  = concentration of thioglycolic acid (mg/ml)  
 $A_x$  = peak area due to thioglycolic acid derivative  
 $A_s$  = response factor (area/unit concentration for thioglycolic acid)

4.3. Standardisation

Approximately 100 mg of thioglycolic acid was accurately weighed into a 100 ml volumetric flask, dissolved in dichloroethane, and diluted to volume with dichloroethane. Volumes of 2, 4 and 8 ml of the standard solution were transferred to 10 ml volumetric flasks and diluted to 8 ml as necessary with dichloroethane. 8 ml of dichloroethane was transferred into a 10 ml volumetric flask as a reagent blank determination. 10 µl of acetic acid was added to each volumetric flask. The standard solutions were treated as in section 3 and finally diluted to 10 ml with dichloroethane.

Three 3 µl aliquots of the standard solutions were injected and the mean peak area for each standard concentration of thioglycolic acid calculated. The response factor ( $A_s$ ) for thioglycolic acid was determined by regression analysis.

## Pathological data relating to individual rats

|               |         |       |                   |       |       |
|---------------|---------|-------|-------------------|-------|-------|
| Group:        | 1       | 2     | 3                 | 4     | 5     |
| Compound:     | -       |       | THIOGLYCOLIC ACID |       |       |
| Level (mg/l): | Control | 0.582 | 0.172             | 0.088 | 0.338 |



## (Pathology - continued)

ControlRat 21<sup>c</sup>

|                              |                            |
|------------------------------|----------------------------|
| <u>Macroscopic findings:</u> | No abnormalities detected. |
| <u>Microscopic findings:</u> |                            |
| Lungs:                       | No abnormalities detected. |
| Liver:                       | No abnormalities detected. |
| Kidneys:                     | No abnormalities detected. |

Rat 22<sup>c</sup>

|                              |                            |
|------------------------------|----------------------------|
| <u>Macroscopic findings:</u> | No abnormalities detected. |
| <u>Microscopic findings:</u> |                            |
| Lungs:                       | No abnormalities detected. |
| Liver:                       | No abnormalities detected. |
| Kidneys:                     | No abnormalities detected. |

Rat 23<sup>c</sup>

|                              |                            |
|------------------------------|----------------------------|
| <u>Macroscopic findings:</u> | No abnormalities detected. |
| <u>Microscopic findings:</u> |                            |
| Lungs:                       | No abnormalities detected. |
| Liver:                       | No abnormalities detected. |
| Kidneys:                     | No abnormalities detected. |

Rat 24<sup>c</sup>

|                              |                            |
|------------------------------|----------------------------|
| <u>Macroscopic findings:</u> | No abnormalities detected. |
| <u>Microscopic findings:</u> |                            |
| Lungs:                       | No abnormalities detected. |
| Liver:                       | No abnormalities detected. |
| Kidneys:                     | No abnormalities detected. |

## (Pathology - continued)

Rat 25<sup>c</sup>Control

|                              |                            |
|------------------------------|----------------------------|
| <u>Macroscopic findings:</u> | No abnormalities detected. |
| <u>Microscopic findings:</u> |                            |
| Lungs:                       | No abnormalities detected. |
| Liver:                       | No abnormalities detected. |
| Kidneys:                     | No abnormalities detected. |

## (Pathology - continued)

ControlRat 26:

Macroscopic findings: No abnormalities detected.  
Microscopic findings:  
Lungs: No abnormalities detected.  
Liver: No abnormalities detected.  
Kidneys: No abnormalities detected.

Rat 27:

Macroscopic findings: No abnormalities detected.  
Microscopic findings:  
Lungs: No abnormalities detected.  
Liver: No abnormalities detected.  
Kidneys: No abnormalities detected.

Rat 28:

Macroscopic findings: No abnormalities detected.  
Microscopic findings:  
Lungs: No abnormalities detected.  
Liver: No abnormalities detected.  
Kidneys: No abnormalities detected.

Rat 29:

Macroscopic findings: No abnormalities detected.  
Microscopic findings:  
Lungs: No abnormalities detected.  
Liver: No abnormalities detected.  
Kidneys: No abnormalities detected.

## (Pathology - continued)

Rat 30:Control

Macroscopic findings: No abnormalities detected.

Microscopic findings:

Lungs: No abnormalities detected.

Liver: No abnormalities detected.

Kidneys: No abnormalities detected.

APPENDIX 2  
(Pathology - continued)

ATO/39

0.582 mg/l

Rat 31<sup>st</sup> - Decedent

Macroscopic findings:

|                      |   |
|----------------------|---|
| External appearance: | Wet fur around snout, jaws and eyes.<br>Redness around snout. |
| Lungs:               | Congested.  |

Microscopic findings:

|          |                            |
|----------|----------------------------|
| Lungs:   | Moderate congestion.       |
| Liver:   | No abnormalities detected. |
| Kidneys: | No abnormalities detected. |

Rat 32<sup>nd</sup> - Decedent

Macroscopic findings:

|                      |   |
|----------------------|---|
| External appearance: | Wet fur around snout, jaws and eyes.<br>Redness around snout. |
| Lungs:               | Congested.  |

Microscopic findings:

|          |                            |
|----------|----------------------------|
| Lungs:   | Moderate congestion.       |
| Liver:   | No abnormalities detected. |
| Kidneys: | No abnormalities detected. |

Rat 33<sup>rd</sup> - Decedent

Macroscopic findings:

|                      |   |
|----------------------|---|
| External appearance: | Wet fur around snout, jaws and eyes.<br>Redness around snout. |
| Lungs:               | Congested.  |

Microscopic findings:

|          |                                   |
|----------|-----------------------------------|
| Lungs:   | Moderate congestion.              |
| Liver:   | No abnormalities detected.        |
| Kidneys: | Minimal bilateral hydronephrosis. |

## (Pathology - continued)

0.582 mg/lRat 34♂ - DecedentMacroscopic findings:

|                      |   |
|----------------------|---|
| External appearance: | Wet fur around snout, jaws and eyes.<br>Redness around snout. |
| Lungs:               | Congested.  |

Microscopic findings:

|          |                            |
|----------|----------------------------|
| Lungs:   | Minimal congestion.        |
| Liver:   | No abnormalities detected. |
| Kidneys: | No abnormalities detected. |

Rat 35♂ - DecedentMacroscopic findings:

|                      |   |
|----------------------|---|
| External appearance: | Wet fur around snout, jaws and eyes.<br>Redness around snout. |
| Lungs:               | Congested.  |

Microscopic findings:

|          |                            |
|----------|----------------------------|
| Lungs:   | Minimal congestion.        |
| Liver:   | No abnormalities detected. |
| Kidneys: | No abnormalities detected. |

## (Pathology - continued)

0.582 mg/lRat 36:✓Macroscopic findings:

External appearance: Red/brown staining around snout and jaws. Wet yellow staining around urogenital region.

Microscopic findings:

Lungs: Minimal congestion.  
Liver: No abnormalities detected.  
Kidneys: No abnormalities detected.

Rat 37: - DecedentMacroscopic findings:

External appearance: Wet fur around snout, jaws and eyes. Redness around snout.  
Lungs: Congested.

Microscopic findings:

Lungs: Minimal congestion.  
Liver: No abnormalities detected.  
Kidneys: No abnormalities detected.

Rat 38: - DecedentMacroscopic findings:

External appearance: Wet fur around snout, jaws and eyes. Redness around snout.  
Lungs: Congested.

Microscopic findings:

Lungs: Minimal congestion.  
Liver: No abnormalities detected.  
Kidneys: No abnormalities detected.

✓ Killed for humane reasons

## (Pathology - continued)

0.582 mg/lRat 39: /Macroscopic findings:

|                      |                                      |
|----------------------|--------------------------------------|
| External appearance: | Wet fur around snout, jaws and eyes. |
| Lungs:               | Very slightly congested.             |

Microscopic findings:

|          |  |
|----------|--|
| Lungs:   | Minimal congestion. Minimal dilatation of bronchiole.                  |
| Liver:   | Moderate pyelitis. Moderate pelvic urothelial hyperplasia, unilateral. |
| Kidneys: | No abnormalities detected.   |

Rat 40: - DecedentMacroscopic findings:

|                      |   |
|----------------------|---|
| External appearance: | Wet fur around snout, jaws and eyes.<br>Redness around snout. |
| Lungs:               | Congested.  |

Microscopic findings:

|          |                            |
|----------|----------------------------|
| Lungs:   | Minimal congestion.        |
| Liver:   | No abnormalities detected. |
| Kidneys: | No abnormalities detected. |

/ Killed for humane reasons



## (Pathology - continued)

0.172 mg/lRat 41<sup>o</sup>

Macroscopic findings: No abnormalities detected.

Microscopic findings:

Lungs: No abnormalities detected.

Liver: No abnormalities detected.

Kidneys: Minimal unilateral hydronephrosis.

Rat 42<sup>o</sup> - Decedent

Macroscopic findings:

External appearance: Wet fur and red/brown staining around snout, jaws and eyes.

Lungs: Congested.

Microscopic findings:

Lungs: Minimal congestion.

Liver: No abnormalities detected.

Kidneys: No abnormalities detected.

Rat 43<sup>o</sup>

Macroscopic findings: No abnormalities detected.

Microscopic findings:

Lungs: No abnormalities detected.

Liver: No abnormalities detected.

Kidneys: No abnormalities detected.

## (Pathology - continued)

0.172 mg/lRat 44 $\sigma$ 

Macroscopic findings: No abnormalities detected.

Microscopic findings:

Lungs: No abnormalities detected.

Liver: No abnormalities detected.

Kidneys: No abnormalities detected.

Rat 45 $\sigma$  - Decedent

Macroscopic findings:

External appearance: Wet fur and red/brown staining around snout, jaws and eyes.

Lungs: Congested.

Microscopic findings:

Lungs: Minimal congestion.

Liver: No abnormalities detected.

Kidneys: No abnormalities detected.

0.172 mg/l

Rat 46:

|                              |                            |
|------------------------------|----------------------------|
| <u>Macroscopic findings:</u> | No abnormalities detected. |
| <u>Microscopic findings:</u> |                            |
| Lungs:                       | No abnormalities detected. |
| Liver:                       | No abnormalities detected. |
| Kidneys:                     | No abnormalities detected. |

Rat 47: - Decedent

|                              |   |
|------------------------------|---|
| <u>Macroscopic findings:</u> |   |
| External appearance:         | Wet fur and red/brown staining around snout, jaws and eyes. |
| Lungs:                       | Congested.  |
| <u>Microscopic findings:</u> |   |
| Lungs:                       | Minimal congestion.   |
| Liver:                       | No abnormalities detected.                                  |
| Kidneys:                     | No abnormalities detected.                                  |

Rat 48:

|                              |                            |
|------------------------------|----------------------------|
| <u>Macroscopic findings:</u> | No abnormalities detected. |
| <u>Microscopic findings:</u> |                            |
| Lungs:                       | No abnormalities detected. |
| Liver:                       | No abnormalities detected. |
| Kidneys:                     | No abnormalities detected. |

## (Pathology - continued)

0.172 mg/lRat 49<sup>2</sup> - DecedentMacroscopic findings:

|                      |   |
|----------------------|---|
| External appearance: | Wet fur and red/brown staining around snout, jaws and eyes. |
| Lungs:               | Congested.  |

Microscopic findings:

|          |   |
|----------|---|
| Lungs:   | Minimal congestion.                                       |
| Liver:   | No abnormalities detected.                                |
| Kidneys: | Minimal enlargement of inner cortical tubular epithelium. |

Rat 50<sup>2</sup>Macroscopic findings:

No abnormalities detected.

Microscopic findings:

|          |                            |
|----------|----------------------------|
| Lungs:   | No abnormalities detected. |
| Liver:   | No abnormalities detected. |
| Kidneys: | No abnormalities detected. |

## (Pathology - continued)

0.068 mg/lRat 51<sup>o</sup>

|                              |                            |
|------------------------------|----------------------------|
| <u>Macroscopic findings:</u> | No abnormalities detected. |
| <u>Microscopic findings:</u> |                            |
| Lungs:                       | No abnormalities detected. |
| Liver:                       | No abnormalities detected. |
| Kidneys:                     | No abnormalities detected. |

Rat 52<sup>o</sup>

|                              |                            |
|------------------------------|----------------------------|
| <u>Macroscopic findings:</u> | No abnormalities detected. |
| <u>Microscopic findings:</u> |                            |
| Lungs:                       | No abnormalities detected. |
| Liver:                       | No abnormalities detected. |
| Kidneys:                     | No abnormalities detected. |

Rat 53<sup>o</sup>

|                              |                            |
|------------------------------|----------------------------|
| <u>Macroscopic findings:</u> | No abnormalities detected. |
| <u>Microscopic findings:</u> |                            |
| Lungs:                       | No abnormalities detected. |
| Liver:                       | No abnormalities detected. |
| Kidneys:                     | No abnormalities detected. |

Rat 54<sup>o</sup>

|                              |                            |
|------------------------------|----------------------------|
| <u>Macroscopic findings:</u> | No abnormalities detected. |
| <u>Microscopic findings:</u> |                            |
| Lungs:                       | No abnormalities detected. |
| Liver:                       | No abnormalities detected. |
| Kidneys:                     | No abnormalities detected. |

## (Pathology - continued)

Rat 55♂0.068 mg/lMacroscopic findings:

No abnormalities detected.

Microscopic findings:

Lungs:

No abnormalities detected.

Liver:

No abnormalities detected.

Kidneys:

No abnormalities detected.

0.068 mg/l

Rat 56:

|                              |                            |
|------------------------------|----------------------------|
| <u>Macroscopic findings:</u> | No abnormalities detected. |
| <u>Microscopic findings:</u> |                            |
| Lungs:                       | No abnormalities detected. |
| Liver:                       | No abnormalities detected. |
| Kidneys:                     | No abnormalities detected. |

Rat 57:

|                              |                            |
|------------------------------|----------------------------|
| <u>Macroscopic findings:</u> | No abnormalities detected. |
| <u>Microscopic findings:</u> |                            |
| Lungs:                       | No abnormalities detected. |
| Liver:                       | No abnormalities detected. |
| Kidneys:                     | No abnormalities detected. |

Rat 58:

|                              |                            |
|------------------------------|----------------------------|
| <u>Macroscopic findings:</u> | No abnormalities detected. |
| <u>Microscopic findings:</u> |                            |
| Lungs:                       | No abnormalities detected. |
| Liver:                       | No abnormalities detected. |
| Kidneys:                     | No abnormalities detected. |

Rat 59:

|                              |                            |
|------------------------------|----------------------------|
| <u>Macroscopic findings:</u> | No abnormalities detected. |
| <u>Microscopic findings:</u> |                            |
| Lungs:                       | No abnormalities detected. |
| Liver:                       | No abnormalities detected. |
| Kidneys:                     | No abnormalities detected. |

(Pathology - continued)

Rat 6090.068 mg/lMacroscopic findings:

No abnormalities detected.

Microscopic findings:

Lungs:

No abnormalities detected.

Liver:

Minimal bilateral hydronephrosis.

Kidneys:

No abnormalities detected.



## (Pathology - continued)

0.338 mg/lRat 61♂ - DecedentMacroscopic findings:

External appearance: Wet fur around snout, jaws and underbody.  
Lungs: Congested.

Microscopic findings:

Lungs: Minimal congestion.  
Liver: No abnormalities detected.  
Kidneys: No abnormalities detected.

Rat 62♂ - DecedentMacroscopic findings:

External appearance: Wet fur around snout, jaws and underbody, red staining around snout.  
Lungs: Congested.

Microscopic findings:

Lungs: Minimal congestion.  
Liver: No abnormalities detected.  
Kidneys: No abnormalities detected.

Rat 63♂ - DecedentMacroscopic findings:

External appearance: Wet fur around snout and jaws.  
Lungs: Congested.

Microscopic findings:

Lungs: Minimal congestion.  
Liver: No abnormalities detected.  
Kidneys: Minimal unilateral hydronephrosis.

## (Pathology - continued)

0.338 mg/lRat 64♂Macroscopic findings:

No abnormalities detected.

Microscopic findings:

Lungs:

No abnormalities detected.

Liver:

No abnormalities detected.

Kidneys:

No abnormalities detected.

Rat 65♂Macroscopic findings:

No abnormalities detected.

Microscopic findings:

Lungs:

No abnormalities detected.

Liver:

No abnormalities detected.

Kidneys:

No abnormalities detected.

## (Pathology - continued)

0.338 mg/lRat 66:

Macroscopic findings: No abnormalities detected.

Microscopic findings:

Lungs: No abnormalities detected.

Liver: No abnormalities detected.

Kidneys: No abnormalities detected.

Rat 67: - Decedent

Macroscopic findings:

External appearance: Wet fur around snout, jaws and eyes.

Lungs: No abnormalities detected.

Microscopic findings:

Lungs: Minimal congestion.

Liver: No abnormalities detected.

Kidneys: No abnormalities detected.

Rat 68: - Decedent

Macroscopic findings:

External appearance: Wet fur around snout, jaws, eyes and urogenital area.

Lungs: No abnormalities detected.

Microscopic findings:

Lungs: Minimal congestion.

Liver: No abnormalities detected.

Kidneys: Minimal enlargement of inner cortical tubular epithelium.

## (Pathology - continued)

0.338 mg/lRat 69<sup>2</sup> - DecedentMacroscopic findings:

|                      |   |
|----------------------|---|
| External appearance: | Wet fur around snout, jaws, eyes and urogenital area. |
| Lungs:               | Slight congestion.                                    |

Microscopic findings:

|          |                            |
|----------|----------------------------|
| Lungs:   | Minimal congestion.        |
| Liver:   | No abnormalities detected. |
| Kidneys: | No abnormalities detected. |

Rat 70<sup>2</sup> - DecedentMacroscopic findings:


|                      |   |
|----------------------|---|
| External appearance: | Wet fur around snout, jaws and urogenital area. |
| Lungs:               | Congestion.                                     |

Microscopic findings:


|          |                            |
|----------|----------------------------|
| Lungs:   | Minimal congestion.        |
| Liver:   | No abnormalities detected. |
| Kidneys: | No abnormalities detected. |




We the undersigned, hereby declare that the work was performed under our supervision according to the procedures herein described, and that this report provides a correct and faithful record of the results obtained.



Graham C. Jackson, B.A., L.R.S.C.,  
Study Director,  
Department of Inhalation Toxicology




Colin J. Hardy, B.Sc., Ph.D., M.I.Biol., C.Biol.,  
Dip.R.C.Path. (Toxicology),  
Head of Industrial Chemicals Unit,  
Department of Inhalation Toxicology



Rupanagudi S. Rao, B.V.Sc., A.H., M.V.Sc., Ph.D.,  
Pathologist



David J. Lewis, B.Sc., Ph.D., M.I.Biol., M.R.C.Path.,  
Deputy Head - Department of Pathology



Chirukandath Gopinath, B.V.Sc., M.V.Sc., Ph.D., F.R.C.Path.,  
Director of Research and Principal Pathologist


## COMPLIANCE WITH GOOD LABORATORY PRACTICE STANDARDS

To the best of my knowledge and belief the study described in this report was conducted in compliance with the following Good Laboratory Practice Standards:

United States Environmental Protection Agency,  
Title 40 Code of Federal Regulations Part 792,  
Federal Register, 29 November 1983

Organization for Economic Co-operation and Development  
ISBN 92-64-12367-9, Paris 1982

Good Laboratory Practice, The United Kingdom Compliance  
Programme, Department of Health & Social Security 1986



Graham C. Jackson, B.A., L.R.S.C.,  
Study Director

13/1/89

Date

## QUALITY ASSURANCE STATEMENT

Certain studies of short duration, such as that described in this report, are conducted at HRC in a setting which involves frequent repetition of similar or identical procedures. At or about the time the study described in this report was in progress, 'process-based' inspections were made by the Quality Assurance Department of critical procedures relevant to this study type. For the inspection of any given procedure, at least one study was selected without bias. The findings of these inspections were reported promptly to the Study Director and to HRC management.

This report has been audited by the HRC Quality Assurance Department. It is considered to be an accurate presentation of the procedures and practices employed during the course of the study and an accurate presentation of the findings.



Peter H.C.V. Richold, B.Sc.,  
Systems Compliance Auditor,  
Quality Assurance Department.

11.1.89

Date



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY  
WASHINGTON, D.C. 20460

C. H. Farr, PhD, DABT  
Manager, Product Safety and Toxicology  
Atochem North America, Inc.  
900 First Avenue  
P.O. Box 1536  
King of Prussia, Pennsylvania 19406-0018

OFFICE OF  
PREVENTION, PESTICIDES AND  
TOXIC SUBSTANCES

MAR 30 1995

EPA acknowledges the receipt of information submitted by your organization under Section 8(e) of the Toxic Substances Control Act (TSCA). For your reference, copies of the first page(s) of your submission(s) are enclosed and display the TSCA §8(e) Document Control Number (e.g., 8EHQ-00-0000) assigned by EPA to your submission(s). Please cite the assigned 8(e) number when submitting follow-up or supplemental information and refer to the reverse side of this page for "EPA Information Requests".

All TSCA 8(e) submissions are placed in the public files unless confidentiality is claimed according to the procedures outlined in Part X of EPA's TSCA §8(e) policy statement (43 FR 11110, March 16, 1978). Confidential submissions received pursuant to the TSCA §8(e) Compliance Audit Program (CAP) should already contain information supporting confidentiality claims. This information is required and should be submitted if not done so previously. To substantiate claims, submit responses to the questions in the enclosure "Support Information for Confidentiality Claims". This same enclosure is used to support confidentiality claims for non-CAP submissions.

Please address any further correspondence with the Agency related to this TSCA 8(e) submission to:

Document Processing Center (7407)  
Attn: TSCA Section 8(e) Coordinator  
Office of Pollution Prevention and Toxics  
U.S. Environmental Protection Agency  
Washington, D.C. 20460-0001

EPA looks forward to continued cooperation with your organization in its ongoing efforts to evaluate and manage potential risks posed by chemicals to health and the environment.

Sincerely,

*Terry R. O'Bryan*  
Terry R. O'Bryan  
Risk Analysis Branch

Enclosure

12988A



Recycled/Recyclable  
Printed with Soy/Canola Ink on paper that  
contains at least 50% recycled fiber



### Triage of 8(e) Submissions

Date sent to triage: \_\_\_\_\_

NON-CAP

~~CAP~~

Submission number: 12988A

TSCA Inventory: Y N D

Study type (circle appropriate):

Group 1 - Dick Clements (1 copy total)

ECO

AQUATO

Group 2 - Ernie Falke (1 copy total)

ATOX

SBTOX

SEN

w/NEUR

Group 3 - Elizabeth Margosches (1 copy each)

STOX

CTOX

EPI

RTOX

GTOX

STOX/ONCO

CTOX/ONCO

IMMUNO

CYTO

NEUR

Other (FATE, EXPO, MET, etc.): \_\_\_\_\_

Notes:

**THIS IS THE ORIGINAL 8(e) SUBMISSION; PLEASE REFILE AFTER TRIAGE DATABASE ENTRY**

#### For Contractor Use Only

entire document: 0 1 2 pages 1,2 pages 1,2,6-7

Notes: 2sided

Contractor reviewer: CPS Date: 12/13/94.

## CECATS TRIAGE TRACKING DBASE ENTRY FORM

CECATS DATA: Submission # BEHQ-0994-12988 SEQ. A

TYPE: INT SUPP FLWP

SUBMITTER NAME: Elf Atochem North

Americas, Inc.

INFORMATION REQUESTED: FLWP DATE:

0501 NO INFO REQUESTED

0502 INFO REQUESTED (TECH)

0503 INFO REQUESTED (VOL. ACTIONS)

0504 INFO REQUESTED (REPORTING RATIONALE)

DISPOSITION:

(639) REFER TO CHEMICAL SCREENING

0678 CAP NOTICE

SUB. DATE: 09/15/94 DATE: 09/28/94 CSRAD DATE: 11/18/94

CHEMICAL NAME:

CASE#

68-11-1

## VOLUNTARY ACTIONS

- 0401 NOT ACTIONED PRIOR TO 11/11  
0402 STUDIOS PLANNING TO REEVALUATE  
0403 PLANNING TO REEVALUATE  
0404 LABORATORY TESTING  
0405 PROFESSIONAL REVIEW  
0406 APP/USE DISCONTINUED  
0407 PRODUCTION DISCONTINUED  
0408 CONFIDENTIAL

| INFORMATION TYPE:             | P F C    | INFORMATION TYPE:              | P F C    |
|-------------------------------|----------|--------------------------------|----------|
| 0201 ONCO (HUMAN)             | 01 02 04 | 0216 EPICLIN                   | 01 02 04 |
| 0202 ONCO (ANIMAL)            | 01 02 04 | 0217 HUMAN EXPOS (PROD CONTAM) | 01 02 04 |
| 0203 CELL TRANS (IN VITRO)    | 01 02 04 | 0218 HUMAN EXPOS (ACCIDENTAL)  | 01 02 04 |
| 0204 MUTA (IN VITRO)          | 01 02 04 | 0219 HUMAN EXPOS (MONITORING)  | 01 02 04 |
| 0205 MUTA (IN VIVO)           | 01 02 04 | 0220 ECOAQUA TOX               | 01 02 04 |
| 0206 REPRO/TERATO (HUMAN)     | 01 02 04 | 0221 ENV. OCCUREL/FATE         | 01 02 04 |
| 0207 REPRO/TERATO (ANIMAL)    | 01 02 04 | 0222 EMER INCI OF ENV CONTAM   | 01 02 04 |
| 0208 NEURO (HUMAN)            | 01 02 04 | 0223 RESPONSE REQUEST DELAY    | 01 02 04 |
| 0209 NEURO (ANIMAL)           | 01 02 04 | 0224 PRODCOMP/CHEM ID          | 01 02 04 |
| 0210 ACUTE TOX. (HUMAN)       | 01 02 04 | 0225 REPORTING RATIONALE       | 01 02 04 |
| 0211 CHR. TOX. (HUMAN)        | 01 02 04 | 0226 CONFIDENTIAL              | 01 02 04 |
| 0212 ACUTE TOX. (ANIMAL)      | 01 02 04 | 0227 ALLERG (HUMAN)            | 01 02 04 |
| 0213 SUB ACUTE TOX (ANIMAL)   | 01 02 04 | 0228 ALLERG (ANIMAL)           | 01 02 04 |
| 0214 SUB CHRONIC TOX (ANIMAL) | 01 02 04 | 0229 METAB/PHARMACO (ANIMAL)   | 01 02 04 |
| 0215 CHRONIC TOX (ANIMAL)     | 01 02 04 | 0230 METAB/PHARMACO (HUMAN)    | 01 02 04 |
|                               |          | 0241 IMMUNO (ANIMAL)           | 01 02 04 |
|                               |          | 0242 IMMUNO (HUMAN)            | 01 02 04 |
|                               |          | 0243 CHEMPHYS PROP             | 01 02 04 |
|                               |          | 0244 CLASTO (IN VITRO)         | 01 02 04 |
|                               |          | 0245 CLASTO (ANIMAL)           | 01 02 04 |
|                               |          | 0246 CLASTO (HUMAN)            | 01 02 04 |
|                               |          | 0247 DNA DAM/REPAIR            | 01 02 04 |
|                               |          | 0248 PROD/USE/PROC             | 01 02 04 |
|                               |          | 0251 MSDS                      | 01 02 04 |
|                               |          | 0259 OTHER                     | 01 02 04 |

## PRODUCTION:

## USE:

## TOXICOLOGICAL CONCERN:

## SPECIES

## ONGOING REVIEW

## TRIAGE DATA: NON-CBI INVENTORY

YES (DROP/REFER)

RAT

LOW

MED Acute Inhalation Toxicity

HIGH

CAS SR

NO

NO (CONTINUE)

REFFR

IN PENDING

12/29/94

12988A

M

Acute inhalation toxicity is of medium concern based on an estimated 4 hour  $LC_{50}$  of 0.21  $g/m^3$  in rats (5/sex/dose). Mortality and corresponding doses ( $g/m^3$ ) were 0/10 (0.068), 4/10 (0.172), 7/10 (0.338) and 10/10 (0.582). Clinical signs included nasal irritation, abnormal respiration, restlessness and hunched posture (all doses). Congested lungs were observed in the decedents.